Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Announces Pricing of $10 Million Public Offering

February 11, 2022

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 – Cannabinoid + Celecoxib Conjugate

February 8, 2022

Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022

January 27, 2022

Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

January 18, 2022

Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

January 6, 2022

Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer

December 6, 2021

Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate

November 18, 2021

Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF

November 8, 2021

Enveric Biosciences to Participate in Wonderland: Miami Conference

October 26, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

October 7, 2021

‹
1
…
10
11
12
13
14
15
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.